Board - Immedica

Thomas Eklund

Chairman of the board

Thomas Eklund has an MBA from Stockholm School of Economics and works as an independent advisor, chairman and investor in Life Science companies. Advisor to Impilo AB and Patricia Industries AB ( Investor AB), Chairman in Sedana Medical AB and Mabtech AB and board member of Biotage AB, Boule Diagnostics AB and Swedencare AB.

Thomas has an extensive background from investments and development of Life Science companies as Head of Investor Growth Capital Europé, AAC Capital, Chairman of Swedish Orphan International, Calliditas, GHP Speciality Care and Biotage.

Simon Angeldorff

Board member

Simon graduated with a M.Sc. in Finance from the Stockholm School of Economics in 1999 – including a CEMS Master from the University of Cologne in 1999 – and with a M.D. from Uppsala University Medical School in 2004. Simon started his career at Goldman Sachs International in London (2001-2003), followed by Altor in 2003-2004 and then joined SEB Enskilda in Stockholm in 2004, with a focus on Nordic healthcare transactions.

In 2008, Simon joined mid-market private equity fund AAC Capital in Stockholm, where he became a Partner in 2011. At AAC, Simon served on the board of Viking, Envirotainer (chairman) and Loparex. In 2013, Simon joined Envirotainer as CEO, a role he held until late 2016.

Magnus Edlund

Board member

Magnus is Impilo’s responsible partner for Immedica and has 12 years of active ownership and governance experience within private equity and healthcare. Prior to joining Impilo in 2017, Magnus worked for Altor Equity Partners between 2009 and 2017 and for the Boston Consulting Group between 2004 and 2009. Magnus currently also serves on the Board of Directors for NutraQ and has previously served on the Boards of Orchid Orthopedics and Rossignol.

Fredrik Holmström

Board observer

Fredrik is an Investment Manager with Impilo and has been working actively with Immedica since its foundation in 2018. Prior to joining Impilo in 2017, Fredrik worked for XIO Group between 2015 and 2017 and for Bank of America Merrill Lynch between 2013 and 2015.

Kerstin Valinder

Board member

Kerstin Valinder Strinnholm brings 30 years of experience from the international pharmaceutical industry. Kerstin was EVP Business development and Corporate strategy in Nycomed Group (now Takeda), joining from AstraZeneca where she had leading positions in marketing and business development. Current assignments include membership of the boards of Camurus AB, Promore Pharma AB, Gedea Biotech AB and Klifo A/S.

Peder Walberg

Board member

Peders background includes being the founder and CEO of Rare Thyroid Therapeutics and Medical Need Europe and co-founder of Wilson Therapeutics. Peder has also served as EVP Business Development and Strategy at Swedish Orphan and Sobi and Nordic Head of New Products and BD&L at Novartis. He has previously been a director of the board of Wilson Therapeutics and OxThera and is currently on the boards of Immedica and PledPharma. Peder is a registered physician with an MD from Uppsala University, a BSc in International Economics and Business Administration from the same university and has a background as a management consultant with the Boston Consulting Group.